440 related articles for article (PubMed ID: 21482565)
21. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
Flamm RK; Sader HS; Jones RN
Braz J Infect Dis; 2013; 17(5):564-72. PubMed ID: 23916453
[TBL] [Abstract][Full Text] [Related]
22. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
Jones RN; Mendes RE; Sader HS
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv17-31. PubMed ID: 21115451
[TBL] [Abstract][Full Text] [Related]
23. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Farrell DJ; Flamm RK; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
[TBL] [Abstract][Full Text] [Related]
24. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline for complicated skin and skin-structure infections.
Nannini EC; Stryjewski ME; Corey GR
Expert Opin Pharmacother; 2010 May; 11(7):1197-206. PubMed ID: 20402556
[TBL] [Abstract][Full Text] [Related]
26. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
27. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
29. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Riccobene T; Jakate A; Rank D
J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
[TBL] [Abstract][Full Text] [Related]
30. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
31. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2013 Apr; 41(4):337-42. PubMed ID: 23466338
[TBL] [Abstract][Full Text] [Related]
32. The problem of complicated skin and skin structure infections: the need for new agents.
Moellering RC
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv3-8. PubMed ID: 21115452
[TBL] [Abstract][Full Text] [Related]
33. Ceftaroline fosamil: a novel broad-spectrum cephalosporin.
Bazan JA; Martin SI
Drugs Today (Barc); 2010 Oct; 46(10):743-55. PubMed ID: 21076711
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
36. Ceftaroline: a new broad-spectrum cephalosporin.
Lim L; Sutton E; Brown J
Am J Health Syst Pharm; 2011 Mar; 68(6):491-8. PubMed ID: 21378297
[TBL] [Abstract][Full Text] [Related]
37. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Med Lett Drugs Ther; 2011 Jan; 53(1356):5-6. PubMed ID: 21252841
[No Abstract] [Full Text] [Related]
38. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
[TBL] [Abstract][Full Text] [Related]
39. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
